Lv3
238 积分 2024-03-06 加入
Team innovation capability: Scale development and validation
2个月前
已完结
Cancer statistics in Chinese older people, 2022: current burden, time trends, and comparisons with the US, Japan, and the Republic of Korea
2个月前
已完结
Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group
3个月前
已完结
Meta‐Analysis of Placebo‐Treated Patients: Dropout Rates From Treatment in MASH Randomised Controlled Trials
4个月前
已完结
Repeating measurements by transient elastography in non‐alcoholic fatty liver disease patients with high liver stiffness
4个月前
已完结
The associations between fibrosis changes and liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease
4个月前
已完结
Oral iptacopan for paroxysmal nocturnal haemoglobinuria—First real‐world experience
6个月前
已完结
Construction and validation of consensus clustering-derived metabolism- and immune-associated genes model for prognosis prediction in cancer patients with liver metastases
10个月前
已完结
Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update
10个月前
已完结
Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402): a multicentre, randomised, controlled phase 2 trial
10个月前
已完结
皖公网安备34019202002308
